Abstracts tagged "Cholesterol and rheumatoid arthritis (RA)"

Abstract Number: 86 • 2018 ACR/ARHP Annual Meeting
Age Dependent Effects of Cholesterol and Smoking on the Risk of Rheumatoid Arthritis in Women – Results from a Nested Case Control Study
Carl Turesson^1,2, Ulf Bergström¹, Jan-Åke Nilsson^1,2 and Lennart Jacobsson³, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Dept of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Smoking is an established risk factor for rheumatoid arthritis (RA). A positive association between body mass index (BMI) and the risk of RA in…
Abstract Number: 2354 • 2018 ACR/ARHP Annual Meeting
Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study
Iris Navarro-Millán^1,2, Sarah Young³, Sally Shurbaji⁴, Chastity McDavid⁴, Anna Cornelius-Schecter², Bernadette Johnson⁴, Andrea Cherrington⁴, Liana Fraenkel⁵, Jeffrey R. Curtis⁴ and Monika M. Safford², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Yale University, New Haven, CT
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 1460 • 2016 ACR/ARHP Annual Meeting
Suppression of Cholesterol Levels and Impairment in Cholesterol Efflux By HDL in K/BxN Mice Is Associated with a Specific Cytokine/Chemokine Profile
Christina Charles-Schoeman¹, Ani Shahbazian², Yuen Yin Lee³, Buzand Oganesian⁴, Victor Grijalva⁵, Anabel Garcia Heredia¹ and Srinivasa T. Reddy⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Medicine-Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³Medicine- Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Medicine-Rheumatology, University of California, Los Angeles, Los ANgeles, CA, ⁵Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Better understanding of lipid metabolism in active rheumatoid arthritis (RA) is needed to understand the cholesterol changes associated with active disease, as well as…
Abstract Number: 1558 • 2015 ACR/ARHP Annual Meeting
Serum Cathepsin S and Cystatin C Relation with Carotid Subclinical Atheromatosis in Rheumatoid Arthritis Patients
Beatriz Tejera Segura¹, De Vera-González AM², Raquel López-Mejías³, Miguel A. Gonzalez-Gay⁴ and Ivan Ferraz-Amaro¹, ¹Division of Rheumatology, University Hospital of Canary Islands, Tenerife, Spain, ²Central Laboratory Division, University Hospital of Canary Islands, Tenerife, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁴Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular risks. Cathepsin S, a cysteine protease implicated in intracellular and extracellular proteolysis,…
Abstract Number: 1681 • 2015 ACR/ARHP Annual Meeting
4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
René Galien¹, Pille Harrison², Reginald Brys², Annegret Van der Aa², Gerben van 't Klooster² and Chantal Tasset², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Patients with active rheumatoid arthritis (RA) present low levels of lipids - total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c) and…
Abstract Number: 1437 • 2014 ACR/ARHP Annual Meeting
Cholesterol Efflux Capacity of HDL and Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Patricia Yancey², Suguru Yamamoto², Annette M. Oeser¹, Tebeb Gebretsadik³, Ayumi Shintani¹, MacRae F. Linton¹, Sergio Fazio¹, Sean Davies¹, L Jackson Roberts II¹, Kasey C. Vickers¹, Paolo Raggi⁴, Valentina Kon¹ and C Michael Stein¹, ¹Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Biostatistics, Vanderbilt University, Nashville, TN, ⁴Emory University, Atlanta, GA
Background/Purpose: Cardiovascular (CV) risk is increased in patients with rheumatoid arthritis (RA), but not fully explained by traditional risk factors such as LDL and HDL…
Abstract Number: 399 • 2014 ACR/ARHP Annual Meeting
Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis
Aulikki Kononoff¹, Hannu Kautiainen², Pasi Soininen^3,4, Antti Kangas^3,4, Leena Laasonen⁵, Leena Arstila^1,6, Pia Elfving¹, Elina Savolainen⁷, Helena Niinisalo^8,9, Mika Ala-Korpela^3,4,10,11 and Oili Kaipiainen-Seppanen¹, ¹Department of Medicine, Kuopio University Hospital, Kuopio, Finland, ²Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ³Computational Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland, ⁴NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁵Helsinki Medical Imaging Center, Helsinki University Hospital, Helsinki, Finland, ⁶Iisalmi Hospital, Iisalmi, Finland, ⁷Kuopio Municipal Hospital, Kuopio, Finland, ⁸Varkaus Hospital, Varkaus, Finland, ⁹Suonenjoki Health Center, Suonenjoki, Finland, ¹⁰Oulu University Hospital, Oulu, Finland, ¹¹Computational Medicine, School of Social and Community Medicine and the Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
Background/Purpose Excess mortality attributed to cardiovascular causes has been described among patients with rheumatoid arthritis (RA). Atherosclerotic lipid profile has been reported in patients with…
Abstract Number: 334 • 2014 ACR/ARHP Annual Meeting
Inflammatory Arthritis in K/BxN Mice Is Associated with Abnormal HDL Function
C. Charles-Schoeman¹, Ani Shahbazian¹, Yuen Yin Lee¹ and Srinivasa T. Reddy², ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose Patients with rheumatoid arthritis (RA) have significantly increased cardiovascular (CV) morbidity and mortality. Abnormal function of high density lipoprotein (HDL) has been implicated as…
Abstract Number: 1256 • 2012 ACR/ARHP Annual Meeting
High Inflammation May Condition the Antiatherogenic Function of Small, Dense HDL in Patients with Active Rheumatoid Arthritis
Carla Saucedo¹, Leonardo gomez Rosso², Tomas Meroño², Fernando Brites², Anatol Kontush³, Luis J. Catoggio⁴, Enrique Soriano⁴, Laurent Camont⁵, Marie Lhomme⁵, Veronica Malah⁶, Patricia Sorroche⁷, Sandrine Chantepie⁵, Paul Robillard⁸ and John Chapman⁵, ¹Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²University of Buenos Aires, Laboratory of Lipids and Lipoproteins, School of Pharmacy and Biochemistry, Buenos Aires, Argentina, ³Université Pierre et Marie Curie-Paris, Paris, France, ⁴Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Université Pierre et Marie Curie, Paris, France, ⁶Rheumatology section, Hospital de Clínicas “José de San Martín”, Buenos Aires, Argentina, ⁷Central Laboratory , Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Université Pierre et Marie Curie, Paris, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality, mainly due to cardiovascular disease. High grade inflammation might drive to premature atherosclerosis. High-density lipoprotein (HDL)…
Abstract Number: 1252 • 2012 ACR/ARHP Annual Meeting
Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Carotid Plaque in Rheumatoid Arthritis
Christina Charles-Schoeman¹, Yuen Yin Lee¹, Veena K. Ranganath¹, John FitzGerald¹, Mihaela B. Taylor², Maureen A. McMahon¹, David Elashoff³ and Srinivasa T. Reddy⁴, ¹University of California, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA, ³Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁴Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is a high density lipoprotein (HDL) associated enzyme, which promotes the anti-oxidant and anti-inflammatory properties of HDL. PON1 polymorphisms and enzyme…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].